Immunome, Inc. (IMNM) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Immunome, Inc. (IMNM) closed at USD 17.20 on 2026-10-14, a change of +4.9 % over the past year, with a market capitalization of USD 2.05B.

Immunome, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Immunome, Inc. key figures

Previous close

USD 17.20 (2026-10-14)

1-year change

+4.9 %

Market cap

USD 2.05B

Enterprise value

USD 1.46B

P/E ratio (trailing)

-7.05

P/E ratio (forward)

-7.17

EPS (trailing)

-2.47

EPS (forward)

-2.43

PEG ratio

n/a

Price to book

3.76

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

13.16

Employees

247

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Immunome, Inc.

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Immunome, Inc. and compare it with other stocks.